A pharmacogenomic test that identifies medications with significant gene-drug interactions to inform prescribing
Access impacts prescribing decisions: Patients whose providers did NOT have access to GeneSight ~two times more likely to receive antidepressant with significant GDIs1
GeneSight helped improve outcomes in multiple clinical studies: Level 1 evidence demonstrates 41% relative improvement in depression remission2